acid, 99.9% ACN; flow rate=0.3 μL/min) for 40 min. A Triple TOF 5600 mass 161 spectrometer was used to analyze the eluted peptides from LC, and each fraction was run 162 twice. The MS data were acquired using the high-sensitivity mode with the following 163 parameters: 30 data-dependent MS/MS scans per full scan, full scans acquired at a 164 resolution of 40,000, MS/MS scans at a resolution of 20,000, rolling collision energy, 165 charge state screening (including precursors with a charge state of +2 to +4), dynamic intensities were used to calculate the relative protein abundance. Then, the protein ratios 183 were quantified by the median of the transformed reporter ion intensity ratios [38, 39] . 185 Multiple reaction monitoring (MRM) was employed to analyze the resulting TMT-186 labeled mass spectrometer data of the significantly changed proteins. Data derived from 187 a spectral library of the urinary proteomics generated by conventional LC-MS/MS using 188 HCD collision were imported into the Skyline software (version 1.1). Skyline was applied 189 to select the most intense transitions for the targeted peptides [40, 41] . The b and y ions of 190 fragments exceeding the m/z ratio of doubly and triply charged peptide precursors were 191 considered. A maximum of five transitions per peptide were traced on a QTRAP 6500 192 mass spectrometer (AB Sciex). The ideal peptides from the target list for building MRM 193 were further optimized using the following criteria: 1) the peptide had no missed cleavage 194 site with trypsin, 2) the peptide was unique to one protein, and 3) the peptide did not 195 contain asparagine, glutamine, methionine. We used the urine samples from the control week group (n=5). p<0.05 (*), p<0.01 (**). 230
184

Multiple reaction monitoring (MRM) confirmation
Serum biochemical parameters 231
The serum levels of specific liver function biomarkers were assayed to determine 232 the liver function of each rat. There was no difference in serum biochemical parameters 233 in the TAA 1-week group and 3-week group compared with those in the respective control 234 groups. However, the TAA 6-week and TAA 8-week groups showed a significant increase 235 in the levels of liver function biomarkers ALT and aspartate transaminase (AST) and a 236 significant decrease in the levels of total protein (TP) and albumin (ALB) compared to 237 those in the respective control groups, indicating hepatocyte damage ( Figure 2 ). spectra between the TAA group and the control group, spectral counting was used to 272 perform a semi-quantitative analysis [35, 42] . The abundance of each protein in a sample 273 was estimated by the mean spectral count of two replicates. chosen for validation, and the data were analyzed by the Skyline software [41] . After the 300 ideal peptides were further optimized for creating the MRM analysis, 57 proteins (47 increased proteins and 10 decreased proteins) were finally used for validation using MRM (Table 1 ). Figure 8 shows 309 several of these proteins. diagnostic value for HCC [69] . Cadherin-17 (CDH17), also called liver-intestine cadherin, 362 is expressed in the liver and intestinal epithelial cells and have a role in the morphological 363 organization of liver and intestine [70] . CDH17 is an oncofetal molecule of HCC by 364 exhibiting elevated expression during embryogenesis and carcinogenesis of the livers and 365 has the potential applicability to be a molecular diagnosing biomarker and target for HCC 366 [71] .
367
There were also some differential proteins discovered in our study that have never 368 been reported to relate to liver fibrosis, such as torsin-1A-interacting protein 2, putative 369 lysozyme C-2, and cathepsin L1. Since these proteins were changed dramatically, they 370 also have the potential to be early urinary biomarkers of liver fibrosis.
371
Discussion
372
Liver fibrosis is one of the major health problems in the world [72] . What is more, 373 liver fibrosis is still reversible, but when it develops into cirrhosis, which is the 374 irreversible end-stage of liver fibrosis, recovery is impossible [49, 58] . For now, liver 375 puncture biopsy is still the gold standard for the diagnosis of liver fibrosis; therefore, the 376 discovery of noninvasive biomarkers is increasingly important [73] . Urine is being 377 recognized as a good source for noninvasive biomarkers because it accumulates the 378 pathological and physiological changes of the body, which are the most fundamental 379 properties of biomarkers [34] . In this study, the TAA-induced liver fibrosis rat model was 380 utilized to simulate the progression of liver fibrosis. This method enabled the 381 identification of differentially expressed proteins by urinary proteomic profiling.
382
Here, the urinary proteomes of rats exposed to TAA for 1 week and 3 weeks were 383 profiled using the TMT-labeled LC-MS-MS method. Several differential proteins were 384 identified between the TAA groups and the control group. The MRM validation of the 385 differentially expressed proteins of the TAA 1-week, 3-week, 6-week and 8-week groups 386 and their relevant control groups further confirmed the results of our proteome analysis.
387
Some of the identified urinary proteins showed a significant expression change (p < 0.05) 388 even in the TAA 1-week group, which was earlier than the appearance of the changes in 389 ALT and AST in the serum and fibrosis in the liver using HE and Masson's staining. 390 Importantly, these results indicated that these urinary proteins have the potential to be a 391 better noninvasive biomarker of liver fibrosis. However, the body weight of the rats was 392 also significantly different in the TAA 1-week group, potentially due to the toxicity of 393 TAA or the influence of the digestive system function, and this change was not specific 394 to liver fibrosis. By decreasing the dosage of TAA according to the body weight of the 395 rats, thereby slowing the disease progression, we may be able to identify earlier changes 396 in urinary proteins before the change in the body weight. In this preliminary study, only 397 one type of liver fibrosis animal model was used for the discovery of urinary biomarkers. [57] FC: fold change; Biomarker: proteins were reported as the biomarkers of liver fibrosis, cirrhosis or other related diseases; Mechanism: proteins make definite effects in the pathologic the mechanism of liver fibrosis.
